{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.4618","value":"7.383"}]}],"title":"Retreatment 1: Physical Health (n = 249)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.0705","value":"5.550"}]}],"title":"Retreatment 1: Mental Health"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.9757","value":"6.018"}]}],"title":"Retreatment 2: Physical Health (n = 255)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.7778","value":"5.746"}]}],"title":"Retreatment 2: Mental Health"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.2326","value":"6.206"}]}],"title":"Retreatment 3: Physical Health (n = 220)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.1916","value":"4.777"}]}],"title":"Retreatment 3: Mental Health"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.9137","value":"5.660"}]}],"title":"Retreatment 4: Physical Health (n = 167)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.2215","value":"4.864"}]}],"title":"Retreatment 4: Mental Health"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.2643","value":"5.038"}]}],"title":"Retreatment 5: Physical Health (n = 124)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.8848","value":"5.141"}]}],"title":"Retreatment 5: Mental Health"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.5370","value":"5.214"}]}],"title":"Retreatment 6: Physical Health (n = 88)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.8556","value":"2.658"}]}],"title":"Retreatment 6: Mental Health"}],"denoms":[{"counts":[{"groupId":"OG000","value":"335"}],"units":"Participants"}],"description":"The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received rituximab 1 g intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants received methotrexate 10-25 mg/week orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid ≥ 5 mg/week or equivalent, given as either a single dose or as divided daily doses.","id":"OG000","title":"Rituximab"}],"paramType":"MEAN","populationDescription":"Intent-to-treat population: All participants who received any part of an infusion of study medication in study WA17531.","reportingStatus":"POSTED","timeFrame":"Baseline to the end of the retreatment period (up to 7 years, 6 months)","title":"Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey","type":"SECONDARY","unitOfMeasure":"Units on a scale"}